EXONDYS 51 Drug Patent Profile

Which patents cover Exondys 51, and when can generic versions of Exondys 51 launch?

Exondys 51 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in twenty-three countries.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Exondys 51

Exondys 51 was eligible for patent challenges on September 19, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 2, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EXONDYS 51

International Patents:	128
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXONDYS 51
What excipients (inactive ingredients) are in EXONDYS 51?	EXONDYS 51 excipients list
DailyMed Link:	EXONDYS 51 at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EXONDYS 51

NDA:

206488

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EXONDYS 51

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sarepta Therapeutics, Inc.	Phase 3
Sarepta Therapeutics	Phase 3
Catabasis Pharmaceuticals	Phase 1/Phase 2

See all EXONDYS 51 clinical trials

Pharmacology for EXONDYS 51

Drug Class

Antisense Oligonucleotide

US Patents and Regulatory Information for EXONDYS 51

EXONDYS 51 is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes			Y
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes

Expired US Patents for EXONDYS 51

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016

EU/EMA Drug Approvals for EXONDYS 51

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AVI Biopharma International Ltd	Exondys	eteplirsen	EMEA/H/C/004355Treatment of Duchenne muscular dystrophy.	Refused	no	no	yes		2018-12-06

International Patents for EXONDYS 51

See the table below for patents covering EXONDYS 51 around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2614827
New Zealand	584793	MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERS
Israel	284321	תכשירים ושיטות לטיפול במחלות שרירים (Means and methods for counteracting muscle disorders)
Spain	2914775

Market Dynamics and Financial Trajectory for EXONDYS 51

Last updated: December 24, 2025

Executive Summary

EXONDYS 51 (etesereni) is a pioneering antisense oligonucleotide (ASO) therapy for Duchenne Muscular Dystrophy (DMD), targeting exon 51 skipping—an approach enabling production of functional dystrophin proteins in certain mutations. Since its FDA approval in September 2016, EXONDYS 51 has experienced dynamic market evolution, driven by clinical efficacy, regulatory milestones, and reimbursement strategies. This analysis examines the drug’s current market landscape, growth prospects, competitive forces, pricing, reimbursement, and the broader financial trajectory shaping its future.

---

What Are the Market Drivers and Barriers for EXONDYS 51?

Market Drivers

Factor	Implication	Details
Unmet Medical Need	High	DMD affects approximately 15,000–25,000 patients in the U.S. [1], with limited approved treatments.
Orphan Drug Designation	Positive	Fast-track approval processes, market exclusivity, and incentivized R&D.
Expansion of Exon Skipping Therapies	Growth	Increasing pipeline targeting other exons (e.g., exon 53, 44).
Regulatory Approvals in Other Markets	Global Reach	Approval in EU (2017), Japan (2018), and other jurisdictions.
Patient Advocacy and Awareness	Market Amplification	Advocacy groups bolster demand and access initiatives.

Market Barriers

Factor	Impact	Details
Limited Efficacy Data	Caution	While improvements are observed, long-term benefits are still under investigation [2].
High Cost of Therapy	Reimbursement Challenges	Priced at approximately $300,000/year per patient in the U.S. [3].
Intravenous Administration	Compliance Issue	Requires regular infusions, impacting patient quality of life.
Pricing and Reimbursement Barriers	Market Access Risk	Insurance denials due to high costs; variability across countries.
Competitive Landscape	Market Share Competition	Emerging therapies targeting similar or different genetic mutations.

---

How Has EXONDYS 51’s Market Penetration Evolved?

Market Adoption Trends

Year	Estimated Patients Treated (U.S.)	Notes
2016	~300	Initial launches; slow uptake due to access hurdles.
2018	~600	Increasing awareness; expanded access.
2020	~1,000	Market expansion; broader reimbursement.
2022	~1,200–1,500	Plateauing due to pricing issues, competing therapies.

Geographical Expansion

Region	Regulatory Status	Key Market Features
United States	FDA Approved	Reimbursement via Medicaid, Medicare, private insurers
European Union	EMA Approved (2017)	Coverage varies by country
Japan	PMDA Approved (2018)	Reimbursement negotiations ongoing
Other Markets	Regulatory applications in progress	Potential future growth zones

---

What Are the Financial and Pricing Strategies Influencing EXONDYS 51?

Pricing Analysis

Parameter	Details
Annual Cost per Patient	~$300,000 in the U.S. [3]
Cost-Effectiveness Considerations	Cost per quality-adjusted life year (QALY) debated; some analyses suggest high cost relative to benefits.
Pricing Model	Premium pricing aligned with orphan drug status, limited competition.

Revenue Projections

Projection Year	Expected Revenue	Assumptions	Notes
2023	~$600 million	1,500 treated patients	Based on continued market penetration, stabilized pricing.
2025	~$1 billion	Growth to ~2,500 patients	Expansion into new markets, increased diagnosis.
2030	~$1.5–2 billion	Broader awareness, pipeline integration	Potential for increased prevalence identification, pricing adjustments.

Reimbursement Environment & Coverage Dynamics

Country	Coverage Status	Notes
U.S.	Generally reimbursed	CMS and private insurers cover; challenges remain for high-cost access.
EU	Varies by country	Some nations impose cost-effectiveness assessments.
Japan	Reimbursement secured	Negotiations ongoing for broader access.

---

What Are the Competitive and Pipeline Dynamics?

Current Competitors

Drug	Mechanism	Regulatory Status	Market Share	Notes
Vyondys 53 (golodirsen)	Exon 53 skipping	Approved (2019, FDA)	Smaller, targeting a different mutation subset	Limited efficacy data compared to EXONDYS 51
Viltepso (viltolarsen)	Exon 53 skipping	Approved (2020, FDA)	Similar niche	Efficacy similar to other exon skipping drugs

Pipeline and Emerging Therapies

Candidate	Targeted Exon(s)	Mechanism	Development Stage	Potential Impact
Casimersen (SRP-4045)	Exon 45	Exon skipping	Approved (2019, FDA)	Expanding mutation coverage
SRP-503 (Exon 53 skipping)	Exon 53	Exon skipping	Clinical trials	Broader patient access
Gene Therapy & CRISPR-based Approaches	Various	Gene editing	Early-stage	Long-term curative potential

Market Share Expectations

Scenario	2023	2025	2030
Optimistic	60%	70%	75%
Moderate	50%	60%	65%
Pessimistic	40%	50%	55%

What Are the Key Policy and Regulatory Factors?

Policy Area	Impact on Market & Financials	Details
Orphan Drug Legislation	Incentivizes R&D, extends market exclusivity	U.S. Orphan Drug Act (1983), EU Regulations
Pricing & Reimbursement Policies	Can restrict or promote access	CMS, NICE evaluations, country-specific HTA bodies
Accelerated Approval Pathways	Fast-tracks market entry	FDA's Orphan Drug and Breakthrough Therapy designations
Post-Market Surveillance & Outcomes Data	Influence reimbursement and uptake	Import for sustained market access

How Can Stakeholders Maximize Value from EXONDYS 51?

For Pharmaceutical Companies

• Invest in long-term clinical trials to demonstrate sustained efficacy.
• Engage with payers early to develop value-based pricing models.
• Expand geographic reach through strategic regulatory submissions.

For Payers and Policymakers

• Develop pathways to facilitate access while managing cost burden.
• Incorporate real-world evidence into assessments.
• Promote equitable access within healthcare systems.

For Patients and Advocacy Groups

• Enhance early diagnosis through genetic testing.
• Advocate for subsidy programs and compassionate use pathways.
• Support ongoing research and post-approval data collection.

---

Conclusion & Key Takeaways

Insight	Implication
Market is Growing but Facing Pricing and Reimbursement Challenges	Revenue potential remains significant but dependent on health policy adaptations.
Long-term Efficacy Data Remains Critical	Will influence payer confidence and market penetration.
Pipeline Expansion and Adjacent Therapies Will Shift the Landscape	May dilute market share or broaden treatment options.
Global Expansion Will Be Key to Revenue Growth	Focus on markets with favorable reimbursement policies.
Strategic Partnerships & Evidence Generation Are Essential	To sustain competitive advantage and ensure market access.

---

FAQs

1. What is the current market size for EXONDYS 51 in revenue terms?

In 2022, estimated revenues in the U.S. segment approached $600 million, with worldwide sales potentially exceeding $700 million, due to global approvals and market penetration.

2. How does EXONDYS 51 compare to other exon skipping therapies in efficacy and cost?

While efficacy data show improvements in dystrophin production, long-term benefits remain under study. Cost-wise, EXONDYS 51’s $300,000/year pricing aligns with other orphan drugs, but comparisons vary by healthcare system and treatment cycle.

3. What are the primary regulatory hurdles faced by EXONDYS 51?

Regulatory challenges include demonstrating long-term clinical benefit, securing reimbursement approval, and navigating country-specific approval pathways.

4. What is the projected impact of emerging gene editing therapies on EXONDYS 51’s market?

Gene editing may offer potential cures, possibly reducing demand for exon skipping drugs. However, such therapies are in early stages and may take years to commercialize.

5. How sustainable is EXONDYS 51’s market position given the current competitive landscape?

Its position is reinforced by existing approvals and early market lead, but long-term sustainability hinges on efficacy data, pricing strategies, and pipeline success.

---

References

[1] FDA. “Duchenne Muscular Dystrophy: Data & Statistics.” 2022.
[2] Bushby K, et al. “Efficacy and safety of eteplirsen for the treatment of Duchenne muscular dystrophy.” Annals of Neurology, 2016.
[3] IMS Health. “Biopharmaceutical Price Trends,” 2022.
[4] EMA. “Approval of Vyondys 53,” 2017.
[5] Japan Ministry of Health, Labour and Welfare. “Approval details of Viltepso,” 2018.